A novel site-targeted ultrasonic contrast agent with broad biomedical application

Circulation

Volumn 94, Issue 12, 1996, Pages 3334-3340

  Lanza, Gregory M ^a   Wallace, Kirk D ^b   Scott, Michael J ^a   Cacheris, William P ^c   Abendschein, Dana R ^d   Christy, Donald H ^a   Sharkey, Angela M ^a   Miller, James G ^b   Gaffney, Patrick J ^e   Wickline, Samuel A ^a,b  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c HemaGen/PFC Inc   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

avidin; contrast media; fibrin; thrombus; ultrasonics

Indexed keywords

AVIDIN; BIOTIN; CHOLESTEROL; CONTRAST MEDIUM; FIBRIN ANTIBODY; FLUOROCARBON; GLYCEROL; PERFLUORODICHLOROOCTANE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; SAFFLOWER OIL; SODIUM CHLORIDE; SURFACTANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY THROMBOSIS; ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; CONTROLLED STUDY; DOG; EMULSION; FIBRIN CLOT; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; SWINE; ULTRASOUND; ULTRASOUND TRANSDUCER;

EID: 8044253414     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.12.3334     Document Type: Article

References (28)

1. Gramiak R, Shah PM. Echocardiography of the aortic root. Invest Radiol. 1968;3:356-366.
2. Bleeker HJ, Shung KK. Ultrasonic characterization of Albunex®, a new contrast agent. J Acoust Soc Am. 1990;87:1792-1797.
3. De Jong N, Hoff L, Skotland T, Bom N. Absorption and scatter of encapsulated gas filled microspheres: theoretical considerations and some measurements. Ultrasonics. 1992;30:95-103.
4. De Jong N, Ten Cate FJ, Lancée CT, Roelandt JRCT, Bom N. Principles and recent developments in ultrasound contrast agents. Ultrasonics. 1991;29:324-330.
5. Kaul S. Quantitation of myocardial perfusion with contrast echocardiography. Am J Curd Imaging. 1991;5:200-216.
6. Feinstein SB. New developments in ultrasonic contrast techniques: transpulmonary passage of contrast agent and diagnostic implications. Echocardiography. 1989;6:27-33.
7. Mattrey RF, Wrigley R, Steinbach GC, Schutt EG, Evitts DP. Gas emulsions as ultrasound contrast agents: preliminary results in rabbits and dogs. Invest Radiol. 1994;29(suppl 2):S139-S141.
8. Goldberg BB, Liu J-B, Burns PN, Merton DA, Forsberg F. Galactose-based intravenous sonographic contrast agent: experimental studies. J Ultrasound Med. 1993;12:463-470.
9. Ophir J, Parker KJ. Contrast agents in diagnostic ultrasound. Ultrasound Med Biol. 1989;15:319-333.
10. Unger E, Shen D, Fritz T, Kulik B, Lund P, Wu GL, Yellowhair D, Ramaswami R, Matsunaga T. Gas-filled lipid bilayers as ultrasound contrast agents. Invest Radiol. 1994;29(suppl 2):S134-S136.
11. Kerber RE, Kioschos JM, Lauer RM. Use of an ultrasonic contrast method in the diagnosis of valvular regurgitation and intracardiac shunts. Am J Cardiol. 1974;34:722-727.
12. Lanza CM, Wallace KD, Scott MJ, Sheehan CK, Cacheris WP, Christy DH, Sharkey AM, Miller JG, Wickline SA. Initial description and validation of a novel site targeted ultrasonic contrast agent. Circulation. 1995;92(suppl 1):I-260. Abstract.
13. Lanza GM, Wallace KD, Abendschein D, Scott MJ, Sheehan CK, Cacheris WP, Christy DH, Sharkey AM, Miller JG, Gaffney PJ, Wickline SA. Specific acoustic enhancement of vascular thrombi in vivo with a novel site-targeted ultrasonic contrast agent. Circulation. 1995;92(suppl I):I-260. Abstract.
14. Wallace KD, Lanza GM, Scott MJ, Holland MR, Christy DH, Sheehan CK, Cacheris WP, Gaffney PJ, Miller JG, Wickline SA. Initial description and validation of a novel site-targeted ultrasonic contrast agent. Circulation. 1995;92(suppl I)I-585. Abstract.
15. Paganelli G, Magnani P, Fazio F. Pretargeting of carcinomas with the avidin-biotin system. Int J Biol Markers. 1993;8:155-159.
16. Paganelli G, Magnani P, Zito F, Villa E, Sudati F, Lopalco L, Rossetti C, Malcovati M, Chiolerio F, Seccamani E, Fazio F. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res. 1991;51:5960-5966.
17. Dosio F, Magnani P, Paganelli G, Samuel A, Chiesa G, Fazio F. Three-step tumor pre-targeting in lung cancer immunoscintigraphy. J Nucl Biol Med. 1993;37:228-232.
18. Modorati G, Brancato R, Paganelli G, Magnani P, Pavoni R, Fazio F. Immunoscintigraphy with three step monoclonal pretargeting technique in diagnosis of uveal melanoma: preliminary results. Br J Ophthalmol. 1994;78:19-23.
19. Tymkewycz PM, Creighton Kempsford LJ, Hockley D, Gaffney PJ. Screen for fibrin specific monoclonal antibodies: the development of a new procedure. Thromb Haemost. 1992;68:48-53.
20. Tymkewycz PM, Creighton Kempsford LJ, Gaffney PJ. Generation and partial characterization of five monoclonal antibodies with high affinities for fibrin. Blood Caagul Fibrinolysis. 1993;4:211-221.
21. Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelel agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation. 1991;83:1048-1056.
22. Romson JL, Haack DW, Lucchesi BR. Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of antithrombotic agents. Thromb Res. 1980;17: 841-853.
23. André MP, Steinbach G, Mattrey RF. Enhancement of the echogenicity of flowing blood by the contrast agent perflubron. Invest Radiol. 1993;28:502-506.
24. McGoron AJ, Pratt R, Zhang J, Shiferaw Y, Thomas S, Millard R. Perfluorocarbon distribution to liver, lung and spleen of emulsions of perfluorotributylamine (FTBA) in pigs and rats and perfluorooctylbromide (PFOB) in rats and dogs by 19F NMR spectroscopy. Artif Cells Blood Substit Immobil Biotechnol. 1994;22: 1243-1250.
25. Flaim SF. Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes. Artif Cells Blood Substit Immobil Biotechnol. 1994;22:1043-1054.
26. Flaim SF, Hazard DR, Hogan J, Peters RM. Characterization and mechanism of side-effects of Imagent® BP (highly concentrated fluorocarbon emulsion) in swine. Invest Radiol. 1991;26:5122-5124.
27. Police AM, Waxman K, Toninaga G. Pulmonary complications after fluosol administration to patients with life threatening blood loss. Crit Care Med. 1985;13:96-98.
28. Clark LC, Hoffmann RE, Davis SL. Response of the rabbit lung as a criterion of safety for fluorocarbon breathing and blood substitutes. Biomat An Cell Immobil Biotechnol. 1992;20:1085-1099.